Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
1. Chardan Research initiated coverage on Praxis Precision Medicines, citing epilepsy franchise potential. 2. Analyst gives a Buy rating and a target price of $80 for PRAX. 3. Praxis has $472 million in cash, funding operations until 2028. 4. Phase 3 study results for ulixacaltamide likely won't meet efficacy endpoints. 5. Vormatrigine shows potential for high sales in epilepsy treatments.